253 related articles for article (PubMed ID: 15606438)
1. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Boffito M; Back D; Stainsby-Tron M; Hill A; Di Perri G; Moyle G; Nelson M; Tomkins J; Gazzard B; Pozniak A
Br J Clin Pharmacol; 2005 Jan; 59(1):38-42. PubMed ID: 15606438
[TBL] [Abstract][Full Text] [Related]
2. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
[TBL] [Abstract][Full Text] [Related]
3. Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.
Ananworanich J; Siangphoe U; Mahanontharit A; Hill A; Hirschel B; Ruxrungtham K
Antivir Ther; 2004 Dec; 9(6):1035-6. PubMed ID: 15651763
[No Abstract] [Full Text] [Related]
4. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
Autar RS; Ananworanich J; Apateerapong W; Sankote J; Hill A; Hirschel B; Cooper D; Lange J; Phanuphak P; Ruxrungtham K; Burger D
J Antimicrob Chemother; 2004 Oct; 54(4):785-90. PubMed ID: 15329366
[TBL] [Abstract][Full Text] [Related]
6. Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
J Antimicrob Chemother; 2005 Apr; 55(4):542-5. PubMed ID: 15722388
[TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.
Chittick GE; Zong J; Blum MR; Sorbel JJ; Begley JA; Adda N; Kearney BP
Antimicrob Agents Chemother; 2006 Apr; 50(4):1304-10. PubMed ID: 16569845
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
von Hentig N; Nisius G; Lennemann T; Khaykin P; Stephan C; Babacan E; Staszewski S; Kurowski M; Harder S; Haberl A
Antivir Ther; 2008; 13(8):1039-46. PubMed ID: 19195329
[TBL] [Abstract][Full Text] [Related]
10. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
12. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
Bittner B; Riek M; Holmes B; Grange S
Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
[TBL] [Abstract][Full Text] [Related]
13. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
14. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
Huang F; Scholl P; Huang DB; MacGregor TR; Taub ME; Vinisko R; Castles MA; Robinson P
Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
[TBL] [Abstract][Full Text] [Related]
15. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
[TBL] [Abstract][Full Text] [Related]
16. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
[TBL] [Abstract][Full Text] [Related]
18. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
Moltó J; Llibre JM; Ribera E; Mínguez C; del Río JS; Pedrol E; Vallecillo G; Cedeño S; Valle M; Miranda C; Negredo E; Clotet B;
J Antimicrob Chemother; 2009 May; 63(5):992-7. PubMed ID: 19279052
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
[TBL] [Abstract][Full Text] [Related]
20. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]